EGFR and neoplasm: Furthermore, the combination therapy of licofelone (a dual COX/LOX inhibitor) with gefitinib (EGFR TKI) showed significant tumour growth inhibition in pancreatic cancer (PC) at a dose lower than doses of the individual agents4,17,.18